Press release
HER2+ Non-Small Cell Lung Cancer Market is expected to reach USD 12.3 billion by 2034
HER2+ Non-Small Cell Lung Cancer Market
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71217
Recent advances in HER2-targeted therapies, antibody-drug conjugates (ADCs), and precision oncology platforms are revolutionizing treatment approaches for HER2-mutant NSCLC. As awareness of biomarker-driven therapies grows and diagnostic technologies expand globally, the HER2 NSCLC market is set for robust growth in the coming decade.
Market Overview
• Market Size 2024: USD 6.2 billion
• Forecast 2034: USD 12.3 billion
• CAGR (2025-2034): 7.1%
The HER2 NSCLC market is expected to grow rapidly, driven by the approval and adoption of HER2 inhibitors and ADCs, increasing biomarker testing, and rising prevalence of lung cancers globally. Expanding access to precision oncology in Asia-Pacific and Latin America is also creating strong opportunities for growth.
Leading Players include: Roche, Novartis, Pfizer, AstraZeneca, Daiichi Sankyo, Merck, Bristol Myers Squibb, and emerging biotech firms specializing in ADC development.
Segmentation Analysis
By Product
• Targeted Therapies (HER2 inhibitors, TKIs)
• Antibody-Drug Conjugates (ADCs)
• Immunotherapies (checkpoint inhibitors, monoclonal antibodies)
• Chemotherapy Agents
• Supportive Care Medications
By Platform
• Hospital Pharmacies
• Specialty Pharmacies
• Online Pharmacies
By Technology
• Precision Oncology Platforms
• Molecular Diagnostics & Genomic Profiling
• Antibody-Drug Conjugate Development
• Immuno-Oncology Technologies
By End Use
• Hospitals & Cancer Centers
• Specialty Oncology Clinics
• Academic & Research Institutes
• Homecare Settings
By Application
• HER2-Mutant NSCLC
• HER2-Overexpressed NSCLC
Summary:
Antibody-drug conjugates (ADCs) such as trastuzumab deruxtecan are reshaping treatment for HER2-mutant NSCLC, offering significant survival benefits. Precision medicine and companion diagnostics are enabling better identification of patients, making biomarker-driven care central to market growth.
Explore Full Report here: https://exactitudeconsultancy.com/reports/71217/her2-non-small-cell-lung-cancer-market
Regional Analysis
North America
• Largest market, driven by rapid adoption of targeted therapies, advanced diagnostics, and presence of major pharmaceutical players.
• Strong FDA approvals for HER2-targeted therapies in lung cancer.
Europe
• Significant share with EMA approvals and reimbursement support for HER2-directed therapies.
• Germany, France, and the UK lead in precision oncology adoption.
Asia-Pacific
• Fastest-growing region due to rising lung cancer prevalence in China, Japan, and India.
• Expanding genomic testing capabilities and government investment in oncology infrastructure support growth.
Middle East & Africa
• Gradual growth due to limited access but increasing oncology specialty centers in Gulf countries.
Latin America
• Moderate growth with Brazil and Mexico leading adoption.
• Rising biomarker testing is expected to accelerate precision therapy uptake.
Regional Summary:
While North America and Europe dominate today, Asia-Pacific is expected to post the fastest CAGR through 2034, fueled by high lung cancer burden and growing adoption of targeted therapies.
Market Dynamics
Key Growth Drivers
• Rising prevalence of lung cancer globally.
• Expanding use of biomarker testing and companion diagnostics.
• Growing adoption of HER2-targeted therapies and ADCs.
• Increasing government and private investment in precision oncology.
Key Challenges
• High costs of targeted therapies and ADCs.
• Resistance development in some patients.
• Limited biomarker testing access in low- and middle-income countries.
Latest Trends
• FDA and EMA approvals of trastuzumab deruxtecan and similar ADCs for HER2-mutant NSCLC.
• Expansion of clinical trials for next-generation HER2 inhibitors.
• Use of AI-driven diagnostics and genomic profiling for precision treatment.
• Collaborations between pharma companies and diagnostic firms to expand testing accessibility.
Get Your Exclusive Offer with up to 10% Discount : https://exactitudeconsultancy.com/checkout/?currency=USD&type=single_user_license&report_id=71217
Competitor Analysis
Major Players in the Market:
• Roche - Leading HER2 portfolio with biologics and ADCs.
• Novartis - Expanding targeted therapy and oncology research.
• Pfizer - Active in immunotherapy and lung cancer R&D.
• AstraZeneca - Strong focus on ADCs and precision oncology.
• Daiichi Sankyo - Key innovator in antibody-drug conjugates.
• Merck - Immunotherapy leader with Keytruda.
• Bristol Myers Squibb - Expanding checkpoint inhibitor and targeted therapy pipeline.
Competitive Dynamics:
The HER2 NSCLC market is highly competitive and innovation-driven, with ADCs and HER2 inhibitors leading the way. Collaborations, licensing deals, and orphan drug designations are strategic priorities among global pharma players.
Conclusion
The HER2 NSCLC market is entering a rapid growth phase with precision oncology at its core. Targeted therapies, ADCs, and immuno-oncology are transforming patient outcomes and expanding treatment possibilities. Despite challenges related to cost and testing access, the outlook through 2034 is highly positive.
Key Takeaways:
• Market projected to grow at a CAGR of 7.1% (2025-2034).
• Antibody-drug conjugates (ADCs) are the fastest-growing product segment.
• North America and Europe dominate adoption, while Asia-Pacific is expected to see the fastest growth.
• Genomic profiling and companion diagnostics are essential to market expansion.
• Pharma competition focuses on ADCs, HER2 inhibitors, and immunotherapy combinations.
Overall, the HER2 NSCLC market represents a significant opportunity in oncology, with innovation in biomarker-driven therapies and precision medicine paving the way for improved survival and better patient outcomes.
This report is also available in the following languages : Japanese (HER2陽性非小細胞肺がん市場), Korean (HER2+ 비소세포 폐암 시장), Chinese (HER2+非小细胞肺癌市场), French (Marché du cancer du poumon non à petites cellules HER2+), German (Markt für HER2+ nicht-kleinzelligen Lungenkrebs), and Italian (Mercato del cancro polmonare non a piccole cellule HER2+), etc.
Request for a sample of this research report at (Use Corporate Mail ID for Quick Response) @ https://exactitudeconsultancy.com/reports/71217/her2-non-small-cell-lung-cancer-market#request-a-sample
Our More Reports:
Severe Toxicities in Lymphoma Market
https://exactitudeconsultancy.com/reports/71575/severe-toxicities-in-lymphoma-market
Soft Tissue Neoplasms Market
https://exactitudeconsultancy.com/reports/71577/soft-tissue-neoplasms-market
T-Cell Blood Cancer Market
https://exactitudeconsultancy.com/reports/71579/t-cell-blood-cancer-market
About Us
Exactitude Consultancy is a market research & consulting services firm which helps its client to address their most pressing strategic and business challenges. Our market research helps clients to address critical business challenges and also helps make optimized business decisions with our fact-based research insights, market intelligence, and accurate data.
https://bulletin.exactitudeconsultancy.com/
https://www.thehealthanalytics.com/
https://www.analytica.global/
https://www.marketintelligencedata.com/
https://www.marketinsightsreports.com/
https://exactitudeconsultancy.com/
Connect Us:
Irfan Tamboli
PHONE NUMBER +1 (704) 266-3234
EMAIL ADDRESS: sales@exactitudeconsultancy.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release HER2+ Non-Small Cell Lung Cancer Market is expected to reach USD 12.3 billion by 2034 here
News-ID: 4162374 • Views: …
More Releases from Exactitude Consultancy
Higher-Risk Chronic Myelomonocytic Leukemia Market is expected to reach USD 2.5 …
Chronic myelomonocytic leukemia (CMML) is a rare hematologic malignancy with overlapping features of myelodysplastic syndromes (MDS) and myeloproliferative neoplasms (MPNs). Patients with higher-risk CMML face a poor prognosis due to aggressive disease progression, limited treatment options, and frequent transformation into acute myeloid leukemia (AML).
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71221
Historically managed with supportive care and hypomethylating agents, higher-risk CMML is now at the forefront of rare blood…
Ependymoma Market Emerging Trends and Growth Prospects 2034
Introduction
Ependymoma is a rare type of tumor arising from the ependymal cells of the central nervous system, often occurring in the brain or spinal cord. Though rare compared to other central nervous system malignancies, it represents a serious challenge due to its heterogeneous nature, recurrence risk, and resistance to conventional therapies. Pediatric patients, particularly children under the age of five, are disproportionately affected, which makes therapeutic innovation even more urgent.
Historically,…
HER2-Positive Early Breast Cancer Market is expected to reach USD 13.5 billion b …
Breast cancer remains the most common cancer among women worldwide, with HER2-positive tumors representing around 15-20% of all breast cancer cases. These tumors are characterized by overexpression of the human epidermal growth factor receptor 2 (HER2), which historically led to aggressive disease progression and poor outcomes.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71219
The introduction of HER2-targeted therapies such as trastuzumab and pertuzumab has transformed HER2-positive breast cancer from…
Hepatocellular Carcinoma Market is expected to reach USD 4.8 billion by 2034
Hepatocellular carcinoma (HCC) is the most common type of primary liver cancer, accounting for nearly 90% of all liver malignancies worldwide. It is strongly linked to underlying liver diseases such as hepatitis B and C infections, alcoholic liver disease, and nonalcoholic steatohepatitis (NASH). Globally, HCC represents a significant healthcare burden, particularly in Asia and Africa, where viral hepatitis prevalence remains high.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/71215
Over…
More Releases for HER2
Evolving Market Trends In The HER2-Positive Breast Cancer Industry: Innovative T …
Our market reports now include the latest updates on global tariffs, trade impacts, and evolving supply chain dynamics.
What Is the Expected HER2-Positive Breast Cancer Market Size During the Forecast Period?
Over the past few years, there has been a noteworthy expansion in the HER2-positive breast cancer market. The market, which is projected to increase from $10.21 billion in 2024 to $10.96 billion in the following year, predicts a compound annual growth…
HER2 Inhibitors: Advancing Breast Cancer Treatments
"The Business Research Company recently released a comprehensive report on the Global HER2 Inhibitors Market Size and Trends Analysis with Forecast 2024-2033. This latest market research report offers a wealth of valuable insights and data, including global market size, regional shares, and competitor market share. Additionally, it covers current trends, future opportunities, and essential data for success in the industry.
Ready to Dive into Something Exciting? Get Your Free Exclusive Sample…
HER2 Positive Breast Cancer Pipeline Drugs 2024
DelveInsight's, "HER2 Positive Breast Cancer Pipeline Insight 2024" report provides comprehensive insights about 60+ companies and 65+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the HER2 Positive Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in…
HER2 Inhibitors: Targeted Therapies Transforming Cancer Treatment
HER2 inhibitors market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the market to account to grow at a CAGR of 9% in the above mentioned forecast period.
Global HER2 Inhibitors Market Scope and Market Size
The HER2 inhibitors market is segmented on the basis of treatment, application, end-users and distribution channel. The growth amongst these segments will help you analyze…
ADC Drugs For HER2 Positive Breast Cancer
According to the latest data, breast cancer has overtaken lung cancer to become the most common cancer among women, and the death rate is the second highest among female tumors, seriously affecting the physical and mental health of women around the world. Patients with abnormal expression of human epidermal growth factor receptor (HER2) account for 15%-20% of all breast cancers, which is highly invasive and has poor prognosis.
Although more drug…
HER2 negative Breast Cancer Pipeline involves 85+ key companies continuously wor …
DelveInsight's HER2 negative Breast Cancer Pipeline Insight 2022 report offers exhaustive global coverage of available, marketed, and pipeline therapies in different phases of clinical development, major pharmaceutical companies working to advance the pipeline space, and future growth potential of the HER2 negative Breast Cancer pipeline domain.
Some of the essential takeaways from the HER2 negative Breast Cancer Pipeline report:
• DelveInsight's HER2 negative Breast Cancer Pipeline analysis depicts a robust space with…
